Target intelligence / Profile preview

Neisseria meningitidis serogroup W-135 capsular polysaccharide (MenW-135 CPS)

Target
MenW-135 CPS
Molecular classification
Bacterial capsular polysaccharide, Antigen, Carbohydrate
01

Overview

The capsular polysaccharide of Neisseria meningitidis serogroup W-135 is a major virulence factor and a key target for active immunization against invasive meningococcal disease. Chemically, it is a repeating disaccharide polymer composed of galactose and sialic acid (N-acetylneuraminic acid) units, which can be variably O-acetylated. This capsule acts as a protective barrier for the bacterium, helping it evade host immune defenses, particularly complement-mediated killing and phagocytosis. However, when purified and administered as a vaccine antigen, either alone or conjugated to a carrier protein (such as diphtheria toxoid, CRM197, or tetanus toxoid), it stimulates the host's immune system to produce protective, complement-mediated bactericidal antibodies. These antibodies specifically recognize and bind to the serogroup W-135 capsule, facilitating bacterial opsonization, phagocytosis, and complement-mediated lysis. Vaccines targeting this polysaccharide, such as Menveo, MenQuadfi, Nimenrix, Penbraya, and Penmenvy, have been highly successful in reducing the incidence of meningitis and septicemia caused by serogroup W-135 Neisseria meningitidis.

Other names
Neisseria meningitidis group W-135 capsular polysaccharide antigenMeningococcal polysaccharide antigen group W-135Meningococcal group W-135 capsular polysaccharideSerogroup W-135 capsular polysaccharide of Neisseria meningitidisMenW-135 capsular polysaccharide
02

Mechanism of action

Active immunization via stimulation of complement-mediated bactericidal antibody production and induction of T-cell dependent immune response when conjugated to a carrier protein.

03

Biological functions

Immune responseBacterial virulenceComplement activationHost-pathogen interaction
04

Disease associations

Infection
05

Safety considerations

Injection site reactionSystemic adverse eventSyncopeHypersensitivityAnaphylaxisReduced immunogenicity in immunocompromised individuals
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

Serum bactericidal antibody titerAnti-capsular IgG antibody level

Beyond the preview

Go deeper on Neisseria meningitidis serogroup W-135 capsular polysaccharide (MenW-135 CPS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neisseria meningitidis serogroup W-135 capsular polysaccharide (MenW-135 CPS).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call